financetom
Business
financetom
/
Business
/
DBS sees rising demand for yuan settlements from Chinese exporters
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DBS sees rising demand for yuan settlements from Chinese exporters
Aug 12, 2025 11:18 PM

SINGAPORE (Reuters) -DBS Group, Southeast Asia's largest lender by assets, is seeing growing interest from Chinese exporters to settle trades in renminbi (RMB), or yuan, particularly with counterparts in Latin America and the Middle East, a senior executive said.

"Right now, you see the Chinese exporters, some are beginning to ask and say, I'm going to sell in RMB, please settle in RMB," said Han Kwee Juan, speaking to Reuters in his first media interview since becoming DBS's group head of institutional banking in January.

"Is that a trend that will continue? I think that it's something that they will continue to ask for as they trade more with the rest of the world, outside of the U.S.," he said.

The shift comes as decades of unwavering faith in the U.S. dollar's dominance in global trade and capital flows faces scrutiny. Major emerging market economies are stepping up efforts to trade in local currencies, underscoring efforts to reduce reliance on the dollar in the global financial system.

However, Han said that most settlements outside of China remain "largely in dollars".

The bank's subsidiary, DBS China, has been a member of China's Cross-Border Interbank Payment System (CIPS) since 2015.

China launched CIPS in 2015 to promote the yuan's usage in international trade. It allows global banks to clear cross-border yuan transactions directly onshore, instead of through clearing banks in offshore yuan hubs.

DBS's settlement flows through the CIPS clearing system grew 30% year-on-year in 2024, Han said, though he maintained that the shift toward more yuan-denominated settlements remains gradual.

In a wide-ranging interview, Han spoke of how businesses are dealing with the uncertainty over Trump's tariffs and outlined DBS's growth strategy in the current economic environment.

"One of the things that we have been growing this year is we have been growing our capability for FI clearing," he said.

"We have been quite purposeful in terms of investment that we have made in the clearing capabilities."

The bank is also looking to capitalise on its institutional banking business to drive its return on equity, which currently stands at 17%, Han said. Last week, DBS posted a quarterly profit that beat estimates, sending its shares to a record high.

"By being able to work with the customers holistically, not just with lending, but also with advisory and as well as cash management, enables us to not only just look at lending or (net interest income) as a source of revenue, but really growing our fee-based revenues," Han said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US labor union backs Norfolk in proxy battle with Ancora
US labor union backs Norfolk in proxy battle with Ancora
Apr 16, 2024
(Reuters) - A top federation of U.S. labor unions has urged Norfolk Southern ( NSC ) shareholders to vote against Ancora's director candidates, arguing the hedge fund's plans for the railroad would compromise safety and improvements being considered. Ancora's proposed strategy for Norfolk Southern ( NSC ) is not fit for purpose and the election of Ancora's proposed directors will...
Sunoco Prices $1.5 Billion Debt Offering
Sunoco Prices $1.5 Billion Debt Offering
Apr 16, 2024
05:54 PM EDT, 04/16/2024 (MT Newswires) -- Sunoco ( SUN ) said late Tuesday it priced a $1.50 billion private offering of senior notes in two tranches at 100% of face value. The offering comprises $750 million of 7% notes due 2029 and $750 million of 7.25% notes due 2032. The company expects the offering to close April 30 and...
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis
Apr 16, 2024
05:51 PM EDT, 04/16/2024 (MT Newswires) -- Alvotech ( ALVO ) and Teva Pharmaceuticals, an affiliate of Teva Pharmaceutical Industries ( TEVA ) said Tuesday that the US Food and Drug Administration approved Selarsdi injection for under-the-skin use to treat moderate to severe plaque psoriasis and active psoriatic arthritis in patients older than six years. Selarsdi is a biosimilar of...
Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing
Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing
Apr 16, 2024
05:50 PM EDT, 04/16/2024 (MT Newswires) -- David P Southwell, Director, on April 12, 2024, sold 80,000 shares in Rocket Pharmaceuticals ( RCKT ) for $1,945,785. Following the Form 4 filing with the SEC, Southwell has control over a total of 114,784 shares of the company, with 114,784 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1281895/000114036124020127/xslF345X03/form4.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved